Last $0.99 USD
Change Today +0.0112 / 1.14%
Volume 510.6K
IMUC On Other Exchanges
Symbol
Exchange
NYSE Amex
Stuttgart
As of 8:04 PM 08/29/14 All times are local (Market data is delayed by at least 15 minutes).

immunocellular therapeutics (IMUC) Snapshot

Open
$0.98
Previous Close
$0.98
Day High
$1.03
Day Low
$0.97
52 Week High
11/26/13 - $4.00
52 Week Low
12/18/13 - $0.65
Market Cap
60.1M
Average Volume 10 Days
284.3K
EPS TTM
$-0.16
Shares Outstanding
60.7M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for IMMUNOCELLULAR THERAPEUTICS (IMUC)

immunocellular therapeutics (IMUC) Related Bloomberg News

View More Bloomberg News

immunocellular therapeutics (IMUC) Related Businessweek News

No Related Businessweek News Found

immunocellular therapeutics (IMUC) Details

ImmunoCellular Therapeutics, Ltd., a clinical-stage biotechnology company, develops immune-based therapies for the treatment of brain and ovarian cancers. Its lead product candidate includes ICT-107, a dendritic cell (DC) vaccine that completed completed Phase II testing trials for the treatment of glioblastoma multiforme (GBM). The company also develops other therapeutic DC vaccines, such as ICT-121 to treat recurrent GBM and other solid tumor cancers, as well as ovarian, pancreatic, and breast cancers; and ICT-140 that targets 7 tumor-associated antigens expressed on ovarian cancer cells. In addition, it has a differential immunization for antigen and antibody discovery platform for discovering monoclonal antibodies for therapeutic and diagnostic development. The company was formerly known as Optical Molecular Imaging, Inc. and changed its name to ImmunoCellular Therapeutics, Ltd. in November 2006. ImmunoCellular Therapeutics, Ltd. is based in Calabasas, California.

3 Employees
Last Reported Date: 03/14/14

immunocellular therapeutics (IMUC) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $527.7K
Founder, Chairman, Chief Scientific Officer a...
Total Annual Compensation: $147.2K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $174.8K
Senior Vice President of Strategic Resources
Total Annual Compensation: $141.3K
Compensation as of Fiscal Year 2013.

immunocellular therapeutics (IMUC) Key Developments

ImmunoCellular Therapeutics, Ltd. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014

ImmunoCellular Therapeutics, Ltd. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. For the quarter ended June 30, 2014, the company incurred a net loss of $2.2 million, or $0.04 per basic and diluted share, compared to a net loss of $150,000, or $0.00 per basic and diluted share for the quarter ended June 30, 2013. The net loss for the second quarter 2014 includes a credit of $249,000 related to the revaluation of the company's warrant derivatives compared to a credit of $2.0 million in the quarter ended June 30, 2013. For the six months ended June 30, 2014, the company incurred a net loss of $5.4 million, or $0.09 per basic and diluted share, compared to a net loss of $5.1 million, or $0.10 for the six months ended June 30, 2013. The net loss for the six months ended June 30, 2014 includes a charge of $167,000 related to the revaluation of warrant derivatives and $312,000 of stock based compensation. For the six months ended June 30, 2014, the company used $5.3 million in cash from operations compared to $4.1 million during the six months ended June 30, 2013.

ImmunoCellular Therapeutics, Ltd. to Report Q2, 2014 Results on Aug 07, 2014

ImmunoCellular Therapeutics, Ltd. announced that they will report Q2, 2014 results at 8:00 PM, GMT Standard Time on Aug 07, 2014

ImmunoCellular Therapeutics, Ltd., Q2 2014 Earnings Call, Aug 07, 2014

ImmunoCellular Therapeutics, Ltd., Q2 2014 Earnings Call, Aug 07, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
IMUC:US $0.99 USD +0.0112

IMUC Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for IMUC.
View Industry Companies
 

Industry Analysis

IMUC

Industry Average

Valuation IMUC Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 2.4x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact IMMUNOCELLULAR THERAPEUTICS, please visit www.imuc.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.